First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

NCT01524991 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Ipilimumab

Sponsor

Hoosier Cancer Research Network

Collaborators

[object Object]